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We compared concurrent combination chemotherapy and radiotherapy with surgery and adjuvant radiotherapy in patients with
stage III/IV nonmetastatic squamous cell head and neck cancer. Patients with non-nasopharyngeal and nonsalivary resectable
squamous cell head and neck cancer were randomised to receive either surgery followed by adjuvant radiotherapy (60Gy over 30
fractions) or concurrent combination chemotherapy and radiotherapy (66Gy in 33 fractions). Combination chemotherapy
comprised two cycles of i.v. cisplatin 20mgm
 2day
 1 and i.v. 5-fluorouracil 1000mgm
 2day
 1, both to run over 96h given on days
1 and 28 of the radiotherapy. A total of 119 patients were randomised. At a median follow-up of 6 years, there was no significant
difference in the 3-year disease-free survival rate between the surgery and concurrent chemoradiotherapy (50 vs 40% respectively).
The overall organ preservation rate or avoidance of surgery to primary site was 45%. Those with laryngeal/hypopharyngeal disease
subsite had a higher organ-preservation rate than the rest (68 vs 30%). Combination chemotherapy and concurrent irradiation with
salvage surgery was not superior to conventional surgery and postoperative radiotherapy for resectable advanced squamous cell head
and neck cancer. However, this form of treatment schedule with a view to organ-preservation can be attempted especially for those
with laryngeal/hypopharyngeal and possibly oropharyngeal disease subsites.
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The majority of the patients with squamous cell head and neck
cancer (SCHNC) present with locally and/or regionally advanced
disease and the use of radical surgery and/or radiotherapy in this
setting yield low locoregional control rates and 5-year survival
rates not exceeding 40%.
The administration of chemotherapy and radiotherapy concur-
rently makes use of the resultant synergistic activity to improve
tumour cell kill. This strategy has found success in anal canal
carcinoma, allowing high cure rates while obviating the need for
radical surgery. Studies carried out in the 1990s using combination
chemotherapy with concurrent radiation in SCHNC have shown
this treatment approach to be feasible despite the significantly
higher toxicity and have produced encouraging results. Adelstein
et al in a phase II trial using cisplatin (CDDP) and 5-fluorouracil
(5FU) combination with concurrent split-course radiotherapy have
reported a 4-year relapse-free survival of 45% and an overall
survival of 49% (Adelstein et al, 1993). This when compared
retrospectively with a similar patient population treated with
radiation alone was shown to be improved. Adelstein next
investigated the use of the same combination regimen concur-
rently with a continuous course of radiotherapy (Adelstein et al,
1994). In 19 patients treated in this fashion, despite significant
toxicity, there were no treatment-related deaths. At a median
follow-up of 20 months, the projected Kaplan–Meier estimate
of locoregional disease control was 92%, with the projected
relapse-free survival of 86%. Of significance was that primary-site
resection was not required in any patient for tumour control. The
same group went on to a phase III randomised study comparing
radiation therapy alone vs concurrent CDDP/5FU and continuous
course radiotherapy in 100 patients with resectable stage III and IV
SCHNC (Adelstein et al, 1997). Salvage surgery was planned for
patients whose disease was not responding or progressing when
re-evaluated at 55 Grays (Gy). At a median follow-up of 3 years, the
3-year projections of relapse-free survival rates were 52% for
patients who received radiotherapy alone and 67% for those who
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sreceived concurrent chemoradiotherapy. Despite the significant
decline in incidence of systemic failure in those who received
chemoradiotherapy, the overall survival was not significantly
different between the two groups. However, if overall survival
with successful primary site preservation was considered,
there was significant benefit in favour of those who received
chemoradiotherapy (35% with radiotherapy alone vs 57% with
chemoradiotherapy).
To date, no group has undertaken a randomised trial to compare
surgery and adjuvant radiation with concurrent chemoradio-
therapy in patients with resectable locally advanced SCHNC. While
it is felt that radical radiotherapy with surgery reserved for salvage
purposes is equivalent in efficacy to surgery followed by radiation,
there has been no randomised trial to support this. Hence, it is
still not established if concurrent chemoradiotherapy as used in
Adelstein et al’s study is superior, or if not, at least equivalent to
surgery upfront followed by adjuvant radiation.
Hence, this study was designed primarily to compare the
efficacy of concurrent use of CDDP/5FU and radical radiotherapy
with surgery upfront followed by adjuvant radiotherapy in patients
with resectable nonmetastatic stage III/IV SCHNC.
PATIENTS AND METHODS
Eligibility criteria
Patients with newly diagnosed, histologically proven, resectable
nonmetastatic stage III/IV SCHNC (excluding nasopharynx and
salivary glands) were eligible. In addition, they need to have good
performance status of ECOG (Eastern Cooperative Oncology Group)
0 or 1, and adequate bone marrow, renal and hepatic function in
order to withstand the rigors of concurrent chemoradiotherapy.
Computed tomography scans, CXR and a triple endoscopy were
requisite staging procedures prior to recruitment. An informed
written consent is required and the protocol was approved by the
respective ethics committee of the participating institutions.
Randomisation and treatment
Patients recruited were randomised to either of the two treatment
arms: the standard arm (S) consisted of radical surgery followed by
adjuvant radiotherapy and the experimental arm (C) consisted of
combination chemotherapy (CDDP/5FU) administered concur-
rently with radical radiotherapy. Stratified randomisation was
carried out using the minimisation method based on the following
factors: primary site (oral cavity/oropharynx vs larynx/hypo-
pharynx vs others) and nodal status (node negative vs node positive).
Surgery included a wide resection of the tumour with
comprehensive neck dissection for unilateral or bilateral disease
as needed. Comprehensive neck dissection for node-positive
disease involved the removal of levels I–V lymph nodes.
Prophylactic neck dissection was carried out for selected N0
disease. Frozen section controlled-margin was used to ensure clear
margins during the surgical procedure. Adjuvant radiotherapy was
given to the primary tumour and upper neck at 2Gy per fraction,
5 days a week to a total of 60Gy in 30 fractions in 6 weeks.
Treatment would commence as soon as adequate healing has been
established and not later than 6 weeks after surgery. Fields were
reduced to exclude the spinal cord at 40Gy and a posterior
electron-matching field was applied. The dose to clinically
uninvolved nodal region was 50Gy. In patients with disease
extending low down the neck, an anterior based AP/PA field was
treated to a dose of 50Gy, to be followed by lateral fields to another
10Gy, which did not include the spinal cord in the treatment
volume. In patients with positive surgical margins, the dose to
the area at risk was brought up to 70Gy using reduced volumes.
The lower neck was treated if there was nodal disease present in
the upper neck. This lower anterior neck was treated at 2Gy per
fraction to a total dose of 50Gy in 25 fractions in 5 weeks.
Patients randomised to arm C would receive two cycles of
chemotherapy comprising CDDP at 20mgm
 2day
 1 and 5FU at
1000mgm
 2day
 1, both given as a continuous intravenous
infusion for 96h on days 1 and 28 of the radiotherapy course.
Radiotherapy in this arm was identical to arm S with the following
exceptions: the total dose to the primary tumour and upper neck
was 66Gy in 33 fractions given in six and a half weeks and involved
nodes received at least 60Gy. Patients with positive nodal disease
at the outset would undergo elective neck dissection 4–6 weeks
postchemoradiotherapy regardless of response.
Follow-up and salvage surgery
Upon completion of the allocated treatment, the patients were
followed up monthly for the first year, two monthly for the second
year, three monthly for the third year and 6 monthly thereafter.
Patients treated on the C arm underwent examination under
anaesthesia about 6–8 weeks post-treatment to evaluate response.
In the presence of persistent disease at the primary site, salvage
surgery would ensue. Those who achieved complete response but
who had nodal disease at the outset would undergo elective neck
dissections regardless of response.
Statistical considerations
It was anticipated that the disease-free survival rate at 3 years with
surgery and adjuvant radiotherapy would be approximately 50%.
Based on the regimen as used by Adelstein et al in their study, a
3-year disease-free survival of about 70% can be expected. In order
to detect a difference of 20% between the two arms, with a two-
sided test size of 5% and power 80%, a recruitment of 200 patients
would be required for this study.
End point definitions
The patient was considered to have an event only if the relapse
occurred after the completion of all primary treatment (i.e. surgery
and radiation for patients randomised to the S arm and
chemoradiotherapy with/without neck dissection or salvage
surgery for persistent disease for patients randomised to the
C arm). For instance, if a patient treated on the C arm failed to
achieve complete response at re-evaluation and the subsequent
salvage surgery was complete, then he would be considered
disease-free. Overall survival is defined as the time from
randomisation to the time when the patient was known to be alive.
RESULTS
Patient cohort
A total of 119 (59 C, 60 S) patients were randomised between
19 August 1996 and 21 February 2002. Due to the slow accrual rate,
the data monitoring committee (DMC) recommended that the
accrual to the study should stop as it was deemed unlikely that the
target could be reached within a reasonable period. One patient in
arm C was ineligible because of confirmed adenocarcinoma by
histology (Figure 1). Two patients randomised to arm C were lost
to follow-up. Nevertheless, they were included in the analysis for
the duration that they were observed. The median follow-up time
was 6 years.
Table 1 shows that the patients in both treatment arms were
comparable in terms of demographic and clinical characteristics.
Their median age was 59 years (range 27–75 years), and well-over
four-fifths of them were males. The racial composition was 80%
Chinese, 11% Indians and 9% Malays.
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sOral cavity (27%), supraglottis (23%) and oropharynx (21%)
were the main sites of disease. Patients were staged according
to the AJCC/UICC system. The majority of the patients had
tumour status of T4 (56%), followed by T3 (26%). In addition,
for most of them, the nodal status was N2 (46%) or N0 (30%).
The distribution of disease stages was 20% Stage III, 75% Stage
IVA and 5% Stage IVB.
Treatment compliance
In total, 50 patients in arm S were treated according to protocol,
receiving both surgery and the recommended dose of adjuvant
radiotherapy. Four patients who declined the randomised regimen
were administered concurrent chemoradiotherapy. Two patients
died before starting the randomised therapy, and one refused the
allocated treatment. One patient declined only surgery, another
only radiotherapy, and yet another was not administered radio-
therapy because of clinical decision (Figure 1). Thus, of the 52
patients who had surgery, the resection was complete for 46,
grossly complete for five (positive margin on paraffin section), and
unresectable for one.
For those randomised to arm C, 41 (70%) received full protocol
treatment. The allocated treatment was not administered to two
patients as one died before starting therapy, while another refused
the randomised option. Other deviations in treatment occurred in
16 patients. Five patients who completed radiotherapy received
Randomised (n=119) 
Allocated to concurrent chemo-RT
(n=59) 
Received concurrent chemo-RT
according to protocol (n=41) 
Did not receive concurrent chemo-RT
(n=2): 
• One died before starting therapy 
• One refused randomised treatment 
Other deviation in treatment (n=16): 
• Five had one cycle of chemotherapy but
   completed RT (two due to refusal of 
   cycle 2, two cardiac problem and one
   pneumonia)  
• Three had dose reduced in cycle 2 due
   to toxicity  
• Two defaulted both cycles of
   chemotherapy but completed RT 
• Two did not complete RT and
   declined one or both cycles of
   chemotherapy 
• Two had delayed cycle(s) due to fever
   and chicken pox respectively 
• Two did not complete or had
   interruption in RT due to severe
   mucositis 
Allocated to surgery + adjuvant RT
(n=60) 
Received surgery + adjuvant RT
according to protocol (n=50) 
Did not receive surgery+adjuvant
RT (n=7): 
•  Four declined randomized therapy,
     and were given chemo-RT instead
•  Two died before starting therapy
•  One refused randomized treatment 
Other deviation in treatment (n=3):
•  One refused surgery 
•  One refused RT 
•  One RT not given due to clinical decision
Lost to follow-up (n=2): 
•  Both nonresidents who have
    returned to home country 
Analysed by intention-to-treat (n=60) 
Analyzed by intention-to-treat (n=59):
Included in analysis: 
•  One ineligible due to adenocarcinoma 
Figure 1 Trial profile.
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sonly one cycle of chemotherapy – two due to refusal of cycle 2, and
one each due to acute myocardial infarction, heart problem or
pneumonia, respectively. The chemotherapy dose was reduced in
cycle 2 for three patients because of toxicity. There were two
patients who completed radiotherapy but defaulted both cycles of
chemotherapy, while another two did not complete radiotherapy
and declined at least one cycle of chemotherapy. Two patients
had delayed cycle(s) due to fever or chicken pox, respectively. In
addition, one patient each did not complete or had interruption in
radiotherapy due to severe mucositis.
In summary, 12% (seven out of 60 patients) of those on arm S
and 12% (seven out of 59 patients) of those on arm C failed to
comply by deciding against recommended treatment while 5%
(three out of 60 patients) of those on arm S and 19% (11 out of 59
patients) on arm C failed to comply due to medical complications.
Treatment toxicity and surgical complications
The toxicity during treatment was classified based on the RTOG
(Radiation Therapy Oncology Group) common toxicity criteria.
There were notably higher incidences of toxicity among patients in
the C arm. A total of eight patients on arm S and 39 on arm C,
experienced toxicity due to radiotherapy and chemoradiotherapy,
respectively. For both groups, the most commonly noted Grade 3
toxicity was mucositis (23 C, 5 S), pharyngitis (20 C, 2 S) and moist
skin desquamation (18 C, 3 S). Details of other types of toxicity are
displayed in Table 2. As noted, all Grade 4 toxicities occurred on
the C arm in eight patients. The most common Grade 4 toxicity
was neutropenic sepsis, involving five patients. Three patients had
Grade 4 neutropenia. There were no toxic deaths from chemo-
radiotherapy.
For patients randomised to arm S, surgical complications were
reported in 14 (27%) patients. One of the complications required
lattisimus dorsi pedicled flap, while the rest included spontaneous
closure of salivary leak, anastomotic breakdown, superficial neck
abscess requiring incision and drainage, complication due to small
salivary fistula, lower lid ectropion, aspirated seroma, pharyngeal
fistula, C5 root paresis on shoulder, left Horner’s syndrome,
wound dehiscence, nasal regurgitation when drinking, wound
infection at the right neck as well as a complication involving right
neck fistulae, bilateral chylothorax and pneumonia. Three of these
14 patients had also experienced Grade 3 toxicity involving moist
skin desquamation, mucositis and/or pharyngitis.
Clinical response to concurrent chemoradiotherapy
An evaluation of all patients on arm C with regard to tumour
response was conducted at 6 weeks post-treatment. Only 56
patients recorded information on tumour response as one patient
died before treatment, another refused the randomised option, and
yet another died before he was evaluated for tumour response.
Table 3 shows that 39 patients responded completely to treatment,
yielding a complete response rate of 70% (95% CI: 57–80%).
Salvage surgery and radical neck dissection
Salvage surgery was performed on eight of 17 patients who had or
were suspected to have failed chemoradiotherapy (Figure 2). This
included one patient for whom salvage surgery was scheduled but
only bilateral radical neck dissection was carried out when frozen
section of the biopsy from the primary site was negative, and
another who had right radical neck dissection only. All of these
patients had partial tumour response. For the six patients who had
salvage surgery of the primary site, complete resection was
attained for all of them. In addition, one each had a bilateral and
Table 1 Patient characteristics by treatment
C( n¼59) S (n¼60) All patients (n¼119)
Age (years)
Median 60 58 59
Range 35–73 27–75 27–75
Sex (%)
Male 51 (86) 53 (88) 104 (87)
Female 8 (14) 7 (12) 15 (13)
Race (%)
Chinese 45 (76) 50 (84) 95 (80)
Indian 8 (14) 5 (8) 13 (11)
Malay 6 (10) 5 (8) 11 (9)
Site of disease (%)
Oral cavity 19 (32) 13 (22) 32 (27)
Oropharynx 12 (20) 13 (22) 25 (21)
Hypopharynx 7 (12) 7 (12) 14 (12)
Supraglottis 13 (22) 14 (23) 27 (23)
Glottis 5 (9) 5 (8) 10 (8)
Subglottis 0 (0) 1 (1) 1 (1)
Maxillary sinus 3 (5) 7 (12) 10 (8)
Tumour status (%)
T1 0 (0) 5 (8) 5 (4)
T2 9 (15) 8 (13) 17 (14)
T3 16 (27) 15 (25) 31 (26)
T4 34 (58) 32 (54) 66 (56)
Nodal status (%)
N0 19 (32) 17 (28) 36 (30)
N1 15 (25) 7 (12) 22 (19)
N2 24 (41) 31 (52) 55 (46)
N3 1 (2) 5 (8) 6 (5)
TNM staging (%)
Stage III 12 (20) 12 (20) 24 (20)
Stage IVA 46 (78) 43 (72) 89 (75)
Stage IVB 1 (2) 5 (8) 6 (5)
Table 2 Grades 3 or 4 toxicity by treatment
CS
Types of toxicity Grade 3 Grade 4 Grade 3 Grade 4
Mucositis 23 0 5 0
Pharyngitis 20 0 2 0
Moist skin desquamation 18 1 3 0
Neutropaenia 4 3 0 0
Anorexia 3 0 0 0
Laryngitis 2 0 1 0
Leucopaenia 1 0 0 0
Thrombocytopaenia 1 0 0 0
Neutropaenic sepsis 0 5 0 0
Other
a 11 0 0
aInclude Grade 3 pneumonia and Grade 4 Hepatitis B.
Table 3 Tumour response for patients on C at 6 weeks post-treatment
Response at 6 weeks N %
Complete response 39 69.6
Partial response 13 23.2
Static disease 1 1.8
Progressive disease 3 5.4
Total 56 100.0
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sa selective neck dissection, and two had comprehensive neck
dissection. Complications occurred in four patients: salivary
fistula, wound breakdown requiring flap reconstruction, a cardiac
complication that resulted in death within a week of surgery and
development of subcutaneous emphysema due to communication
with tracheostomy tube. Four of the eight patients who had
undergone salvage surgery and/or radical neck dissection due to
failed chemoradiotherapy later experienced local relapse, two
developed distant metastases and one died of other causes.
Of the remaining nine patients on arm C who did not respond to
treatment, salvage surgery was not carried out because of lung
metastasis (four patients), stroke (one patient), valvular heart
disease (one patient) and refusal of treatment (three patients). The
latter three patients, together with the one who had stroke,
developed loco-regional disease. Two patients each had distant
relapse, as well as loco-regional and distant relapses.
In accordance to the protocol, patients with nodal disease at
diagnosis who attained complete response after chemoradio-
therapy were to undergo elective neck dissection. Of the 39 patients
with complete response, 11 were of N1 and 17 N2. However, radical
neck dissection was performed on 22 (nine N1, 13 N2). There were six
cases of complications: wound breakdown requiring flap revision,
right carotid blow-out, chyle leak, postoperative pyrexia and
thrombophlebitis, pneumonia as well as wound dehiscence. Of the
remaining six patients who did not have RND, the respective reasons
for five of them were patient refusal (two cases), development of
bronchopneumonia, death from heart failure 1 month after comple-
tion of chemoradiotherapy, decision of the attending surgeon not to
proceed and unknown for one patient.
Salvage surgery was also performed on three of six patients who
subsequently developed local relapse after an initial complete
response. Of these three, one developed a second local relapse after
salvage surgery, while another died within a month following
salvage surgery from a tracheo-inominate fistula as a result of
surgical complication. Of the three patients who did not undergo
salvage surgery, one refused while the other two were deemed
unresectable due to extent of local recurrence.
Thus, among a total of 33 patients who had undergone salvage
surgery and/or radical neck dissection, 11 complications were
reported in all, yielding a surgical complication rate of 33%.
Altogether, 23 of 54 patients on arm C who were evaluable for
primary site organ preservation remained free from salvage
surgery (Table 4). All of them responded completely to treatment
and had no local relapse. The overall rate of avoidance of surgery
∗  These were the four patients for whom
  salvage surgery was not peformed
  because they developed lung
  metastases.
17 failed treatment 
Salvage surgery (n = 8): 
• Salvage surgery ± neck
dissection (n = 6): 
   All complete resection 
   Two no neck dissection 
   Two comprehensive neck dissection 
   One bilateral neck dissection 
   One selective neck dissection 
•
•
•
•
Radical neck dissection only (n = 
2): 
   One bilateral neck dissection 
   One right radical neck dissection 
No salvage surgery (n = 9) 
Reason for no salvage: 
•  Four developed lung metastasis 
•  One died of stroke
•  One died of valvular heart disease 
•  One refused further treatment 
•  One scheduled for radical neck
    dissection, but defaulted treatment 
•  One lost to follow-up 
Complications (n =4): 
•  One develop subcutaneous
   emphysema
•  One cardiac complication (30-day
   mortality)
•  One wound breakdown  
•  One salivary fistula 
Outcomes: 
Six relapses 
  Four loco·regional 
  Two distant 
One died of cardiac complication  
One died of pneumonia 
Outcomes: 
•  Eight relapses 
    Four loco-regional 
    Two distant ∗ 
    Two loco-regional and distant ∗ 
•  One died of valvular heart disease 
Figure 2 Outcome of patients in C requiring salvage surgery.
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swas 42% (95% CI: 30–56%). This rate appears to vary with the site
of disease, with the laryngeal/hypopharyngeal patients reporting
the highest avoidance rate of 62% (95% CI: 41–79%).
Site of relapse
A total of 57 patients (30 C, 27 S) had relapsed after completion of
treatment. Table 5 shows the distribution of site of first relapse.
Loco-regional relapse was the most common, occurring in 34 (19
C, 15 S) patients. This was followed by distant metastasis,
frequently at the lung, which occurred in 20 patients (10 C, 10
S). There were three (1 C, 2 S) cases of relapse involving both loco-
regional and distant metastases.
Disease-free survival (DFS)
The Kaplan–Meier DFS curves for the two treatment groups are
shown in Figure 3. The median disease-free survival time was 1.6
years for arm C and was not reached for arm S. The 3-year DFS
rates for the two groups were 43% for C and 54% for S. This
difference was not statistically significant.
Overall survival (OS)
At the time of analysis, 77 (39 C, 38 S) patients have died (Table 6).
The distribution of cause of death was similar between the two
treatment arms. The most common cause was local recurrence,
occurring in 27 (13 C, 14 S) patients. There were also 14 (7 C, 7 S)
patients who died of both local recurrence and distant metastasis.
Of the 27 who died of other causes, five were cardiac-related (2 C, 3
S) and seven were due to pneumonia (4 C, 3 S). Figure 4 compares
the Kaplan–Meier OS curves for the two treatment groups. The
median overall survival time for arm C was 2.2 years. For those
who were randomised to arm S, the median survival time was 2.7
years. The 3-year survival rates for the two groups were 40% for
arm C and 50% for arm S. The difference was not statistically
significant.
DISCUSSION
For various reasons, the management of SCHNC poses a
significant challenge to the physician and to society as a whole.
This condition tends to occur in the socio-economically deprived
segment of the population and comorbidities such as cardio-
vascular disease and chronic obstructive airway disease are
frequent in this group due to the pervasive damage from
tobacco usage. These two factors can pose significant impediments
to radical therapeutic maneuvers and hence eligibility for accrual
to clinical trials.
This study, the first attempt ever to compare the upfront surgery
and adjuvant radiotherapy with concurrent chemoradiotherapy as
primary treatment, faced several problems. The slow accrual rate
reflects the unwillingness of patients to have their treatment
subject to randomisation. A significant number of patients who
were approached for recruitment would prefer to make the choice
themselves when given two treatment alternatives.
Table 4 Avoidance of salvage surgery at primary site
Site of disease Estimate of proportion 95% CI
Total 23/54
a (43%) 30–56%
Laryngeal 13/21 (62%) 41–79%
Hypopharynx 3/7 —
Supraglottis 7/11 —
Glottis 3/3 —
Nonlaryngeal 10/33 (30%) 17–47%
Oral cavity 4/19 —
Oropharynx 6/11 —
Maxillary sinus 0/3 —
aInformation not available on five patients – one died before starting therapy, one
died before evaluation for response, two had complete response, but one was later
lost to follow-up and two died of unknown causes.
Table 5 Site of first relapse
Site C S Total
Loco-regional 19 15 34
Distant metastasis 10 10 20
Both 1 2 3
Total 30 27 57
Table 6 Survival status by treatment
C( n¼59) S (n¼60) Total (n¼119)
Alive
Disease-free 18 22 40
With local
recurrence
00 0
With distant
metastasis
00 0
With both local and
distant recurrences
00 0
Dead
Of local recurrence 13 14 27
Of distant metastasis 5 4 9
Of both local and
distant recurrences
77 1 4
Other cause
a 14 13 27
Lost to follow-up 2 0 2
aCause of death was not known for one each in C and S arm.
012 456 8
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No. at risk (any relapse) 
S
C
58(0)
58(0)
36(20)
31(20)
29(4)
22(8)
23(2)
15(1)
18(1)
11(1)
17(0)
10(0)
10(0)
8(0)
3(0)
1(0)
S 
C 
P = 0.425 
HR: 1.2 (95% CI%: 0.7−2.1)
37
Figure 3 Disease-free survival by treatment. Three patients in S relapsed
before completion of radiotherapy. The date of surgery was thus taken as
the date of treatment completion. Another patient who died within a week
of completion of salvage surgery was considered disease-free.
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sNoncompliance with allocated treatment was proportionately
high. Noncompliance because of decision by the patients against
accepting all or part of the recommended treatment was equal
in both arms. However, medical complications interfering wholly
or partly with the allocated treatment were significantly more
common in those randomised to chemoradiotherapy. This
observation underscores the significant toxicities associated with
such an intense treatment and this could limit the assessment of
the true efficacy of this treatment strategy. The development of
severe oropharyngeal mucositis often limits the dose and the
number of cytotoxic agents that can be used with concurrent
radiation to the head and neck region. The frequent coexisting
medical conditions in patients with SCHNC could also have
contributed to the high morbidities associated with chemora-
diotherapy. Nevertheless, 53 patients (90%) received at least one
cycle of the combination chemotherapy regimen concurrent with
radiotherapy and no treatment-related deaths were encountered
(Figure 1). Adelstein et al (1994) administered two cycles of 5FU
and CDDP on days 1 and 21 of radiation to his cohort of patients,
which is more intense than our study. Yet they were able to achieve
100% compliance rate with the chemotherapy and radiation doses.
Although the toxicity was significant with 37% neutropaenic rate,
no toxic deaths were encountered. In contrast, our experience with
a similar, albeit less intense regimen has been less favourable. Only
69% of our patients who received chemoradiotherapy were able
to complete the preplanned chemotherapy and radiation doses.
It is difficult to offer a clear explanation for this difference. One
possible explanation is that our institution is a public institution
that caters to the lower socioeconomic group of patients and
compromised socioeconomic support may have an adverse impact
on treatment compliance. Another possible reason is the ethnic
difference between the two groups. However, there is currently
scarce data to support ethnic differences in handling the cytotoxics
used in the two studies.
Another important observation from our study is the rather
limited ability of surgery to salvage recurrence or persistent
disease successfully (see Figure 2). The high complication rate plus
the high relapse rate after salvage surgery contributes to this high
failure rate. Again, our experience with salvage surgery in patients
who received chemoradiotherapy as primary treatment differs
significantly from that of Adelstein’s group (Adelstein et al, 2000).
Among the 17 patients who failed concurrent chemoradiotherapy
in our study, salvage was possible in only 47% of these patients.
There were no long-term disease-free survivors in this group of
patients (see breakdown in Figure 2). In contrast, salvage surgery
was successful in at least local control in eight out of 11 patients
(73%) who received chemoradiotherapy in Adelstein et al’s study.
This difference can be explained at least in part by the fact that the
two studies are not comparable in the type of patients selected.
Firsty, oropharyngeal, hypopharyngeal and laryngeal subsites
comprised the vast majority (96%) of the patients in Adelstein
et al’s study compared to 56% in our study. Secondly, those with
T4 lesions made up only 33% of the patients in Adelstein et al’s
study compared to 56% in our study. These differences in patient
factors and the inability to deliver the planned doses of cytotoxics
could have resulted in a significantly poorer outcome of our
patients with a 3-year overall survival rate of 40% when compared
to 60% in Adelstein et al’s study (Adelstein et al, 1997).
Our study failed to show an advantage with the use of aggressive
combination chemotherapy with concurrent radiotherapy
although it is difficult to conclude firmly on this because the
accrual target was not reached. As stated above, the patients in
our study were mainly those with bulky disease. Hence, it is
conceivable that chemoradiotherapy is less likely to lead to
complete pathological response in such bulky disease. Radical
surgery upfront could be a better approach.
Two studies were published back-to-back recently addressing
the role of adjuvant chemoradiotherapy (Bernier et al, 2004;
Cooper et al, 2004). The US RTOG/Intergroup study and EORTC
study have similar study design where a randomised comparison
was made between the standard adjuvant radiotherapy and the
adjuvant CDDP with concurrent radiotherapy. Both studies are
also similar in certain outcomes, namely a significantly improved
disease-free or progression-free survival and significantly in-
creased treatment-related toxicities both in the combined modality
arms. The US study reported 2% treatment-related death rate in
the combined arm (Cooper et al, 2004). Despite the smaller sample
size, the EORTC study was able to show a significant difference in
overall survival rate at 5 years (53 vs 40%) in favour of the
combined arm while the US study could not. This divergence may
appear puzzling, but the difference in the composition of the
patient population in both studies could account for this. The
proportion of patients with laryngeal/hypopharyngeal cancers was
clearly lower in the US study (127 out of 416 or 30%) compared
with the EORTC study (143 out of 334 or 43%). The EORTC study
does suggest that the incorporation of all three modalities may
provide an advantage as dual modalities regardless of the
scheduling or modalities used have not been shown conclusively
to result in improved overall survival outcome in most randomised
studies conducted to date. This makes sense, as locally advanced
SCHNC is largely a locoregional problem that requires aggressive
locoregional therapy to tackle effectively.
Should we consider organ preservation at all for the patients with
the appropriate subsites (i.e. larynx or hypopharynx) with bulky
disease? This goal is attainable based on the results of our study.
However, attempting to preserve organ in patients with bulky
disease should be carried out with proper patient selection and close
follow-up. Our data suggest that patients with disease involving the
laryngeal/hypopharyngeal subsites were more likely to achieve this
goal. Another potential candidate is the oropharyngeal subsite with
organ preservation successful in 55% of such patients.
A main criticism with the design of this study is the
heterogeneity of the disease subsites included. Although confining
the study population to one or two disease subsites is ideal and
would increase the robustness of the results, we felt that doing so
would curtail the accrual rate significantly. Moreover, based on the
promising results shown by Adelstein et al in their studies, the
primary objective of this study was to compare the efficacy of
concurrent chemoradiotherapy as primary treatment with upfront
surgery followed by adjuvant radiotherapy in patients with locally
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sadvanced resectable disease and not organ preservation. However,
even the inclusion of heterogeneous subsites did not help us attain
the accrual target over the 5-year study period. It is unlikely that a
study of similar design can be replicated.
In conclusion, surgery remains an important modality in the
management of patients with locally advanced SCHNC, especially
those with bulky, yet resectable disease. Concurrent chemoradio-
therapy is an effective form of treatment schedule but is limited by
its significant toxicities especially in patients who are often
compromised by other comorbidities. Experience and availability
of good nursing and paramedical supports are necessary requisites
to carry out this treatment schedule safely.
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